Vivek Subbiah shared a post on X:

“Thrilled to be featured in American Association for Cancer Research (AACR)’s special issue of Cancer Discovery! Our in focus special commentary, ‘A Vision for Democratizing Next-Generation Oncology Clinical Trials’ published simultaneously with the meeting. Will be featured in the giant screen at the plenary session tomorrow.
Huge thanks to AACR24 and the Cancer Discovery team, Elizabeth McKenna and Tali Lev for this forward-thinking initiative!”

Source: Vivek Subbiah/X

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. Dr. Vivek Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in-human and practice-changing studies that directly led to approvals from the FDA, European Medicines Agency, and other agencies across the world. He is an expert in tumor agnostic precision oncology and leads the BRAF and RET tissue agnostic studies to FDA approval.